Kidney Cancer – Pipeline Review, H1 2012 by GlobalMarketsDirect

VIEWS: 2 PAGES: 284

More Info
									Kidney Cancer – Pipeline Review, H1 2012




                     Kidney Cancer – Pipeline Review, H1 2012


                                                                                          Reference Code: GMDHC1632IDB
                                                                                            Publication Date: January 2012




Kidney Cancer – Pipeline Review, H1 2012                                                   GMDHC1632IDB / Pub January 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                            Page(1)
Kidney Cancer – Pipeline Review, H1 2012




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ............................................................................................................................................................................... 10
    List of Figures .............................................................................................................................................................................. 14
Introduction....................................................................................................................................................................................... 15
    Global Markets Direct Report Coverage ...................................................................................................................................... 15
Kidney Cancer Overview .................................................................................................................................................................. 16
Therapeutics Development............................................................................................................................................................... 17
    An Overview of Pipeline Products for Kidney Cancer .................................................................................................................. 17
Kidney Cancer Therapeutics under Development by Companies .................................................................................................... 19
Kidney Cancer Therapeutics under Investigation by Universities/Institutes...................................................................................... 27
Late Stage Products ......................................................................................................................................................................... 39
    Comparative Analysis .................................................................................................................................................................. 39
Mid Clinical Stage Products.............................................................................................................................................................. 40
    Comparative Analysis .................................................................................................................................................................. 40
Early Clinical Stage Products ........................................................................................................................................................... 41
    Comparative Analysis .................................................................................................................................................................. 41
Discovery and Pre-Clinical Stage Products ...................................................................................................................................... 42
    Comparative Analysis .................................................................................................................................................................. 42
Kidney Cancer Therapeutics – Products under Development by Companies .................................................................................. 43
Kidney Cancer Therapeutics – Products under Investigation by Universities/Institutes ................................................................... 52
Companies Involved in Kidney Cancer Therapeutics Development ................................................................................................. 79
    Bristol-Myers Squibb Company ................................................................................................................................................... 79
    Genzyme Corporation ................................................................................................................................................................. 80
    Boehringer Ingelheim GmbH ....................................................................................................................................................... 81
    F. Hoffmann-La Roche Ltd. ......................................................................................................................................................... 82
    Kyowa Hakko Kirin Co., Ltd. ........................................................................................................................................................ 83
    Amgen Inc. .................................................................................................................................................................................. 84
    AstraZeneca PLC ........................................................................................................................................................................ 85
    Eli Lilly and Company .................................................................................................................................................................. 86
    GlaxoSmithKline plc .................................................................................................................................................................... 87
    Seattle Genetics, Inc. .................................................................................................................................................................. 88
    Genentech, Inc. ........................................................................................................................................................................... 89
    Merck & Co., Inc. ......................................................................................................................................................................... 90
    Emergent BioSolutions Inc. ......................................................................................................................................................... 91
    Oxford BioMedica plc .................................................................................................................................................................. 92
    Light Sciences Oncology, Inc. ..................................................................................................................................................... 93
    Novartis AG ................................................................................................................................................................................. 94
    ImClone Systems Incorporated ................................................................................................................................................... 95
    Astellas Pharma Inc..................................................................................................................................................................... 96
    Eisai Co., Ltd. .............................................................................................................................................................................. 97
    Ono Pharmaceutical Co., Ltd....................................................................................................................................................... 98
    OSI Pharmaceuticals, Inc. ........................................................................................................................................................... 99



Kidney Cancer – Pipeline Review, H1 2012                                                                                                     GMDHC1632IDB / Pub January 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                   Page(2)
Kidney Cancer – Pipeline Review, H1 2012



    Pfizer Inc.................................................................................................................................................................................... 100
    Taiho Pharmaceutical Co., Ltd. ................................................................................................................................................. 101
    Exelixis, Inc................................................................................................................................................................................ 102
    Alfacell Corporation ................................................................................................................................................................... 103
    Celgene Corporation ................................................................................................................................................................. 104
    Bayer AG ................................................................................................................................................................................... 105
    MannKind Corporation............................................................................................................................................................... 106
    3SBio Inc. .................................................................................................................................................................................. 107
    EntreMed, Inc. ........................................................................................................................................................................... 108
    Celldex Therapeutics, Inc. ......................................................................................................................................................... 109
    Active Biotech AB ...................................................................................................................................................................... 110
    AEterna Zentaris Inc. ................................................................................................................................................................. 111
    AIDA Pharmaceuticals, Inc. ....................................................................................................................................................... 112
    Lorus Therapeutics Inc .............................................................................................................................................................. 113
    Bionomics Limited ..................................................................................................................................................................... 114
    Northwest Biotherapeutics, Inc. ................................................................................................................................................. 115
    Cleveland BioLabs, Inc. ............................................................................................................................................................. 116
    Patrys Limited ............................................................................................................................................................................ 117
    Keryx Biopharmaceuticals, Inc. ................................................................................................................................................. 118
    ARQULE, INC............................................................................................................................................................................ 119
    Allos Therapeutics, Inc .............................................................................................................................................................. 120
    Flamel Technologies S.A........................................................................................................................................................... 121
    Dendreon Corporation ............................................................................................................................................................... 122
    Green Cross Corporation .......................................................................................................................................................... 123
    MOLOGEN AG .......................................................................................................................................................................... 124
    OncoTherapy Science, Inc. ....................................................................................................................................................... 125
    Threshold Pharmaceuticals, Inc. ............................................................................................................................................... 126
    Innate Pharma SA ..................................................................................................................................................................... 127
    Protox Therapeutics Inc............................................................................................................................................................. 128
    Rexahn Pharmaceuticals, Inc. ................................................................................................................................................... 129
    Debiopharm Group .................................................................................................................................................................... 130
    Antisense Pharma GmbH .......................................................................................................................................................... 131
    Wilex AG ................................................................................................................................................................................... 132
    Philogen S.p.A. .......................................................................................................................................................................... 133
    Cadila Pharmaceuticals Ltd. ...................................................................................................................................................... 134
    ERYtech Pharma ....................................................................................................................................................................... 135
    immatics biotechnologies GmbH ............................................................................................................................................... 136
    Curacyte AG .............................................................................................................................................................................. 137
    Argos Therapeutics, Inc............................................................................................................................................................. 138
    Cytheris SA................................................................................................................................................................................ 139
    Altor BioScience Corporation..................................................................................................................................................... 140
    AgrenVec, S.L. .......................................................................................................................................................................... 141
    Alethia Biotherapeutics Inc. ....................................................................................................................................................... 142
    Gene Signal International SA. ................................................................................................................................................... 143


Kidney Cancer – Pipeline Review, H1 2012                                                                                                     GMDHC1632IDB / Pub January 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                  Page(3)
Kidney Cancer – Pipeline Review, H1 2012



    MacroGenics, Inc....................................................................................................................................................................... 144
    Pivotal BioSciences, Inc. ........................................................................................................................................................... 145
    Neotropix, Inc. ........................................................................................................................................................................... 146
    Jennerex Biotherapeutics, Inc. .................................................................................................................................................. 147
    Endocyte, Inc. ............................................................................................................................................................................ 148
    Advenchen Laboratories, LLC ................................................................................................................................................... 149
    Immutep S.A. ............................................................................................................................................................................. 150
    Syndax Pharmaceuticals, Inc. ................................................................................................................................................... 151
    Esperance Pharmaceuticals, Inc. .............................................................................................................................................. 152
    Welichem Biotech Inc. ............................................................................................................................................................... 153
    Tigris Pharmaceuticals, Inc........................................................................................................................................................ 154
    AVEO Pharmaceuticals, Inc. ..................................................................................................................................................... 155
    KAHR medical Ltd. .................................................................................................................................................................... 156
    Advanced Cancer Therapeutics ................................................................................................................................................ 157
    Medical Enzymes AG ................................................................................................................................................................ 158
    IkerChem S.L............................................................................................................................................................................. 159
    Immunovative Therapies, Ltd. ................................................................................................................................................... 160
Kidney Cancer – Therapeutics Assessment ................................................................................................................................... 161
    Assessment by Monotherapy Products ..................................................................................................................................... 161
    Assessment by Combination Products ...................................................................................................................................... 162
    Assessment by Route of Administration .................................................................................................................................... 163
    Assessment by Molecule Type .................................................................................................................................................. 166
Drug Profiles................................................................................................................................................................................... 169
    Nexavar - Drug Profile ............................................................................................................................................................... 169
        Product Description............................................................................................................................................................... 169
        Mechanism of Action ............................................................................................................................................................. 169
        R&D Progress ....................................................................................................................................................................... 169
    Axitinib - Drug Profile ................................................................................................................................................................. 171
        Product Description............................................................................................................................................................... 171
        Mechanism of Action ............................................................................................................................................................. 171
        R&D Progress ....................................................................................................................................................................... 171
    Axitinib - Drug Profile ................................................................................................................................................................. 173
        Product Description............................................................................................................................................................... 173
        Mechanism of Action ............................................................................................................................................................. 173
        R&D Progress ....................................................................................................................................................................... 173
    Sutent - Drug Profile .................................................................................................................................................................. 175
        Product Description............................................................................................................................................................... 175
        Mechanism of Action ............................................................................................................................................................. 175
        R&D Progress ....................................................................................................................................................................... 175
    ANYARA - Drug Profile .............................................................................................................................................................. 177
        Product Description............................................................................................................................................................... 177
        Mechanism of Action ............................................................................................................................................................. 177
        R&D Progress ....................................................................................................................................................................... 177
    IMA901 - Drug Profile ................................................................................................................................................................ 178


Kidney Cancer – Pipeline Review, H1 2012                                                                                                   GMDHC1632IDB / Pub January 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                 Page(4)
Kidney Cancer – Pipeline Review, H1 2012



        Product Description............................................................................................................................................................... 178
        Mechanism of Action ............................................................................................................................................................. 178
        R&D Progress ....................................................................................................................................................................... 178
    TroVax - Drug Profile ................................................................................................................................................................. 179
        Product Description............................................................................................................................................................... 179
        Mechanism of Action ............................................................................................................................................................. 179
        R&D Progress ....................................................................................................................................................................... 179
    NuLeusin - Drug Profile ............................................................................................................................................................. 181
        Product Description............................................................................................................................................................... 181
        Mechanism of Action ............................................................................................................................................................. 181
        R&D Progress ....................................................................................................................................................................... 181
    Tivozanib - Drug Profile ............................................................................................................................................................. 182
        Product Description......................................................
								
To top